CompletedPhase 3NCT02375828

Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels

Studying Neonatal diabetes mellitus

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Assistance Publique - Hôpitaux de Paris
Principal Investigator
Michel Polak, MD, PhD
Hopital Universitaire Necker Enfants Malades, Assistance publique - hôpitaux de Paris, Faculté de medicine Paris Descartes, Université Sorbonne Paris cité
Intervention
Glibenclamide(drug)
Enrollment
10 target
Eligibility
18 years · All sexes
Timeline
2015 – 2019

Study locations (1)

Collaborators

URC-CIC Paris Descartes Necker Cochin

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02375828 on ClinicalTrials.gov

Other trials for Neonatal diabetes mellitus

Additional recruiting or active studies for the same condition.

See all trials for Neonatal diabetes mellitus →

← Back to all trials